Abstract
Adenosine triphosphate-binding cassette transporter G2 (ABCG2) is expressed on the cerebrospinal fluid (CSF) side of choroid plexus epithelial cells, which form the blood-CSF barrier. Raltegravir was recently identified as a substrate of ABCG2. In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens. The mean CSF raltegravir concentration was significantly lower in CA (25.5 ng/mL) and AA (<10 ng/mL) genotypes at position 421 in ABCG2 gene compared with CC (103.6 ng/mL) genotype holders (P = 0.016).
Original language | English |
---|---|
Pages (from-to) | 484-486 |
Number of pages | 3 |
Journal | Journal of Acquired Immune Deficiency Syndromes |
Volume | 66 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2014 Aug 15 |
Keywords
- Adenosine triphosphate-binding cassette transporter G2
- Antiretroviral therapy
- Blood-cerebrospinal fluid barrier
- Cerebrospinal fluid concentrations
- Raltegravir
ASJC Scopus subject areas
- Infectious Diseases
- Pharmacology (medical)